icon-folder.gif   Conference Reports for NATAP  
 
  17th European AIDS Conference
November 6-9
2019, Basel
Back grey_arrow_rt.gif
 
 
 
Outcomes for Women in Phase 3 Trials of Long-Acting Cabotegravir
+ Rilpivirine: Pooled ATLAS and FLAIR Week 48 Results

 
 
  17th EACS 2019 Nov 6-9 Basel
Reported by Jules Levin
 
Romina Quercia,1 Chloe Orkin,2 Ronald D'Amico,3 Joseph M. Mrus,3 Sterling Wu,4 Amy Cutrell,3 Ken Chow,5 Joseph W. Polli,3 David A. Margolis,3 Peter Williams,6 Annemiek de Ruiter,1 Kimberly Smith,3 William R. Spreen3
 
1ViiV Healthcare, Research Triangle Park, Brentford, UK; 2Queen Mary University, London, UK; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4GlaxoSmithKline, Collegeville, PA, USA; 5GlaxoSmithKline, Mississauga, Ontario, Canada; 6Janssen Research & Development, Beerse, Belgium

1108191

1108192

1108193

1108194

1108195

1108196

1108197